By Michael T. SullivanPublished October 21, 2018 10:10:23The latest on the brain and the brain’s latest hit, the next big trend in brain chemistry is a product that may help people with headaches forget.
According to a report in The Lancet, scientists have created a molecule that can reverse the symptoms of chronic pain, including chronic migraines.
The study, published in the journal Science, involved injecting the molecule into mice with a protein that stimulates nerve cells to become less sensitive to pain.
It then gave the mice a drug with similar effects.
Researchers said the molecule could be used to treat conditions such as depression, PTSD and anxiety.
“It may help us in the future to reduce our pain,” said researcher Robert Zuckerman of the University of California, San Diego.
“This molecule, the dendritic-prosthetic drug, was tested in animals and we believe it will be able to overcome a number of neurodegenerative diseases.”
The study also found that the drug could help the body recover from chronic pain.
The drug works by preventing the body from releasing endorphins, a chemical signal that can be used by neurons to signal pain.
Endorphins can also make neurons more sensitive to nerve stimulation, which in turn can help the brain function normally.
“These drugs are being used in a variety of diseases to treat pain, such as cancer, HIV/AIDS and other diseases, but they have yet to be tested on humans,” said Dr. David Wiedenkamp, a neuroscientist at the University College London.
“With the study, we have demonstrated that we can make a molecule which can work against the normal neurochemical pathways and reverse the effects of chronic painful neurodegenesis.”
He added that the next step for the research was to test the drug on humans.
“To our knowledge, this is the first study of a synthetic drug to reverse pain and the results are exciting,” he said.
Zuckerman’s team is also developing a similar drug to help people who suffer from severe headaches, but the team is still waiting for results.
“We are hopeful that the study will provide some clues to the neurobiology of migraine, such that we may be able find better therapies to treat these chronic pain conditions,” he told The Associated Press.
The researchers are now exploring the potential use of the drug in humans.
If the treatment does work, Zuckman’s team said it could be a game changer for the brain.
“Our work is part of a revolution in the way we treat pain in the brain,” Zuckmann said.
“This is the beginning of a new era in medicine.”